A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease

Overview of attention for article published in Kidney International, August 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users
facebook: 1 Facebook page

guideline: 1 clinical guideline source
bluesky: 2 Bluesky users

Readers on

mendeley: 110 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 53,532 followers.

https://t.co/J2bX7oQhcH Cotadutide seems to be promising for the future! How can we decide SD in sample size determination? How do they calculate SD in the paper?

@Kidney_Int @pi_ronco @BradRovin @Evans__lab @UMNews @UMNkidney @UMNSurgery @edinburgh_renal @DrDKavanagh @VickyBrockleba1 @docsallyj @Larrypedkid @OhioStateNeph @APHP @Inserm @RagliantiV @AngelottiLucia @MarcoAllinovi @AManonelles @crz_garrit @FrancescaB…

RT @Ryu04196650Ryu: DKDに対するGLP-1/Glucagon Receptor Agonistのcotadultide @Kidney_Int (2024) A randomized phase 2b trial examined the effects…

DKDに対するGLP-1/Glucagon Receptor Agonistのcotadultide @Kidney_Int (2024) A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney diseas…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.